T2 Mapping (relaxometry)

Quibim
Quibim has developed this suite to automatically obtain the T2 mapping of tumors and depict changes and abnormalities with AI segmentation. The analysis of T2 mapping provides imaging biomarkers for the assessment and monitoring of solid tumors, such as prostate cancer, rectal cancer and liver cancer, among others.
Information source: Vendor
Last updated: Feb. 11, 2022

General Information

General
Product name T2 Mapping (relaxometry)
Company Quibim
Subspeciality Abdomen, Breast
Modality MR
Disease targeted Solid tumors, Prostate cancer, Rectal cancer, Endometrial cancer, Liver cancer
Key-features T2 values, T2 Histogram
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand) (Need to draw ROI)

Technical Specifications

Data characteristics
Population Assessment and monitoring of solid tumors and cartilage changes
Input MRI T2 Multi-echo
Input format
Output One-page structured report: ROI, T2 map, T2 histogram, T2 fitting, statistics summary
Output format
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically after drawing ROI
Processing time 1 - 10 minutes

Regulatory

Certification
CE
Certified, Class IIa , MDD
FDA No or not yet
Intended Use Statements
Intended use (according to CE) Quibim Precision® is an image processing software package to be used by trained professionals including but not limited to physicians and medical technicians. The software runs in the browser of a standard “off-the-shelf” computer and can be used to perform image viewing, processing, and analysis of medical images. Data and images are acquired through DICOM compliant imaging devices and modalities

Market

Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 2
Paying clinical customers (institutes) 5+
Research/test users (institutes)
Pricing
Pricing model License
Based on Number of installations, Number of analyses

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Crema MD et al. Articular cartilage in the knee: current MR imaging techniques and applications in clinical practice and research. RadioGraphics 2011;31:37-61.

Sanz-Requena R et al. Modification of longitudinal relaxation time (T1) as a biomarker of patellar cartilage degeneration. Radiologia 2010;52:221-227.

Sanz R et al. MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. J Magn Reson Imaging 2008;27:171-177.